Safety and effectiveness assessment of the surpass evolve (SEASE): a post-market international multicenter study
- Juan Vivanco-Suarez 1, Mahmoud Dibas 1, Demetrius Klee Lopes 2, Ricardo A Hanel 3, Mario Martínez-Galdámez 4, Aaron Rodriguez-Calienes 1, Gustavo M Cortez 3, Johanna T Fifi 5, Alex Devarajan 5, Gabor Toth 6, Thomas Patterson 6, David Altschul 7, Vitor M Pereira 8, Eileen Liu 8, Ajit S Puri 9, Anna Luisa Kuhn 9, Waldo R Guerrero 10, Priyank Khandelwal 11, Ivo Bach 11, Peter Kan 12, Gautam Edhayan 12, Curtis Given 13, Sandra Narayanan 14, Bradley A Gross 15, Mudassir Farooqui 1, Milagros Galecio-Castillo 1, Shahram Derakhshani 16, Santiago Ortega-Gutierrez 17
- 1Department of Neurology, Neurosurgery & Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
- 2Department of Neurosurgery, Advocate Aurora Health Inc, Park Ridge, Illinois, USA.
- 3Department of Neurosurgery, Lyerly Neurosurgery, Jacksonville, Florida, USA.
- 4Department of Interventional Neuroradiology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
- 5Department of Neurosurgery, Mount Sinai Health System, New York, New York, USA.
- 6Cerebrovascular Center, Cleveland Clinic, Cleveland, Ohio, USA.
- 7Department of Neurosurgery, Montefiore Medical Center, New York, New York, USA.
- 8Department of Neurosurgery, St Michael's Hospital, Toronto, Ontario, Canada.
- 9Department of Radiology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- 10Department of Neurology and Brain Repair, University of South Florida, Tampa, Florida, USA.
- 11Department of Neurosurgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.
- 12Department of Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
- 13Department of Radiology, Baptist Health Lexington, Lexington, Kentucky, USA.
- 14Neurointerventional Program and Comprehensive Stroke Program, Pacific Neuroscience Institute, Santa Monica, California, USA.
- 15Department of Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- 16Department of Diagnostic and Therapeutic Neuroradiology, Queen's University Hospital, Romford, UK.
- 17Department of Neurology, Neurosurgery & Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA santy-ortega@uiowa.edu.
- 0Department of Neurology, Neurosurgery & Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The Surpass Evolve (SE) flow diverter shows high effectiveness in treating intracranial aneurysms (iAs), with a 73% complete occlusion rate. This study confirms its favorable safety profile in real-world international use.
Area Of Science
- Endovascular neurosurgery
- Cerebrovascular disease management
- Medical device technology
Background
- Intracranial aneurysms (iAs) are a significant cause of morbidity and mortality.
- Flow diverters represent a first-line treatment for specific iAs.
- Limited data exists on the new-generation Surpass Evolve (SE) 64-wire flow diverter.
Purpose Of The Study
- To evaluate the safety and effectiveness of the Surpass Evolve (SE) flow diverter.
- To report the first international real-world experience with the SE device.
- To assess complete occlusion rates and major adverse events following SE implantation for iAs.
Main Methods
- A multicenter, retrospective, international, post-marketing cohort study (SEASE) was conducted.
- Consecutive patients treated with SE for iAs between 2020-2022 were included.
- Primary endpoints were complete aneurysm occlusion (Raymond-Roy Class 1) and major safety events (ischemia, hemorrhage, mortality).
Main Results
- 305 patients with 332 iAs were treated with SE.
- Median follow-up was 10.2 months, with 73.0% complete occlusion rate.
- Major stroke occurred in 2% and procedure-related mortality in 0.7% of cases.
Conclusions
- The Surpass Evolve (SE) flow diverter demonstrates high effectiveness in achieving complete occlusion of intracranial aneurysms.
- SE exhibits a favorable safety profile, with low rates of major ischemic events and mortality.
- This study supports the use of SE as a reliable treatment option for intracranial aneurysms in real-world clinical practice.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
01:23
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:15
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Survival Times Are Positively Skewed
Survival times often exhibit positive skewness, unlike the normal distribution assumed...

